Department of Radiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Shouwa-ku, Nagoya, Aichi, 466-8550, Japan.
Radiat Oncol. 2012 Aug 1;7:122. doi: 10.1186/1748-717X-7-122.
The purpose of this study is to analyze the outcome of patients with early glottic cancer (GC) treated with radiotherapy (RT) with or without chemotherapy at 10 institutions in the Tokai District, Japan.
Ten institutions combined data from 279 patients with T1-T2 GC treated with RT with or without chemotherapy between 2000 and 2005. The overall survival rate, disease-specific survival rate, and local control rate were evaluated in 270 patients, except for incomplete cases due to issues such as discontinuation, using the method of Kaplan-Meier and compared using the log-rank test. Results were considered statistically significant at the level of p < 0.05.
For 122 patients, the tumors were classified as T1a, while 64 patients had T1b tumors, and 84 patients had T2 tumors. In three cases of T1 tumors, the subtype was unknown. Combined chemoradiotherapy (CRT) was administered during each stage, and various chemotherapy drugs and regimens were used. The median follow-up period was 55.4 months. The 5-year LC rates for T1a, Tb, and T2 tumors in all patients were 87.9%, 82.7%, and 74.1%, respectively. The difference between T1a and T2 was statistically significant (p = 0.016). The 5-year LC rates for T1a, Tb, and T2 with CRT were 92.7%, 78.6%, and 80.7%, respectively, while the rates with radiation alone were 86.5%, 83.8%, and 64.4%, respectively. The difference between CRT and RT alone was not statistically significant in each stage.
In this survey, CRT was performed for early GC at most institutions in clinical practice. Our data showed no statistical difference in the LC rates between CRT and RT alone in each stage. However, there was a tendency for the LCRs of the CRT group to be more favorable than those of the RT group in the T2-stage.
本研究旨在分析日本东海地区 10 家机构对早期声门癌(GC)患者采用放化疗与单纯放疗的治疗效果。
10 家机构联合分析了 2000 年至 2005 年间采用放化疗与单纯放疗治疗的 279 例 T1-T2GC 患者的数据。270 例患者的总生存率、疾病特异性生存率和局部控制率通过 Kaplan-Meier 法进行评估,对于因中断等原因不完全的病例则不予考虑,使用对数秩检验进行比较。结果以 p < 0.05 为具有统计学意义。
122 例患者肿瘤为 T1a 期,64 例为 T1b 期,84 例为 T2 期。3 例 T1 期肿瘤的亚型不详。各期均行联合放化疗(CRT),采用了多种化疗药物和方案。中位随访时间为 55.4 个月。所有患者中 T1a、T1b 和 T2 肿瘤的 5 年 LC 率分别为 87.9%、82.7%和 74.1%,T1a 与 T2 之间差异有统计学意义(p = 0.016)。T1a、T1b 和 T2 期 CRT 组的 5 年 LC 率分别为 92.7%、78.6%和 80.7%,单纯放疗组的 5 年 LC 率分别为 86.5%、83.8%和 64.4%,各期 CRT 与 RT 之间差异无统计学意义。
在本研究中,大多数机构在临床实践中对早期 GC 采用 CRT。我们的数据显示,各期 CRT 与 RT 之间的 LC 率无统计学差异。然而,T2 期 CRT 组的 LC 率有优于 RT 组的趋势。